QIAGEN And Pathway Diagnostics Sign Agreement To Address Biomarker Development Needs In Pharma
Unique Offering Will Enhance Clinical Development and Validation of Biomarkers in Global R&D Programs and Clinical Trials
Venlo, The Netherlands - QIAGEN N.V., a provider of molecular diagnostics products and the world's premier supplier of solutions for preanalytical sample preparation, and Pathway Diagnostics Corporation (Malibu, CA), a pioneer in biomarker development and testing services for the pharmaceutical industry, today announced a co-marketing partnership. The new partnership allows customers in the biotechnology and pharmaceutical industries to leverage QIAGEN's sample and assay technology platforms in combination with Pathway Diagnostics' clinical development and testing service capabilities. Under the partnership, QIAGEN‘s global pharmaceutical sales channel and resource network will develop project opportunities which can be addressed together with the service capabilities of Pathway Diagnostics.
The pharmaceutical industry is currently accelerating its focus on the co-development and co-validation of biomarker assays with therapeutics. These biomarker assays are intended to improve drug development efficiency by improving patient selection and clinical trial outcomes, accelerating time-to-market cycles for new drugs, and reducing clinical trial costs. In some cases, biomarker development may lead to companion diagnostic products that will be utilized as a prerequisite for therapeutic intervention.
QIAGEN currently offers a broad portfolio of sample and assay technologies that are considered standards in biomarker development and routinely used in the pharmaceutical industry. Pathway Diagnostics is a leading service provider for biomarker development. QIAGEN and Pathway Diagnostics expect to have a significant impact on critical needs emerging in pharma to establish the clinical utility of new biomarkers through comprehensive assay development, sample-to-result qualification and clinical validation of genetic, pharmacogenomic, metabolomic, and toxicogenomic biomarkers in cancer, infectious disease, central nervous system disorders, cardiovascular disease, and other drug development programs in the pharmaceutical industry.
"We are very pleased to enter into this partnership with Pathway Diagnostics and believe that this offers a novel and unique value proposition for our customers in the pharmaceutical and biotechnology industries," said Peer Schatz, QIAGEN's Chief Executive Officer. " Pathway and QIAGEN share the vision that biomarker development and testing is at the forefront of accelerating drug development and providing clinical diagnostic value leading to improved patient care and associated therapeutic intervention. Pathway's biomarker expertise and QIAGEN's global reach will allow our shared vision to be realized. "
"Pathway is pleased to be teaming with QIAGEN, a worldwide leader of sample and assay technologies for the pharmaceutical industry, "said Walter Narajowski, President and CEO of Pathway Diagnostics. "QIAGEN's global reach in pharma, and its ability to provide technology and industry leading solutions along the complete continuum from research through drug development into clinical diagnostics, combined with Pathway Diagnostics' broad experience and infrastructure for performance of clinical assay services is a winning combination to accelerate translational and personalized medicine initiatives for the pharmaceutical industry. "
SOURCE: QIAGEN N.V.